New Medicines discover that two desks can work together
New Medicines could reach NHS patients three to six months faster after two regulators agreed to assess different parts of the process in parallel. Britain has finally discovered that two escalators can move at once without alarming science.
MHRA assesses whether medicines are safe and effective. NICE considers value for NHS use in England. The plan allows earlier information sharing and parallel decisions, while keeping both crucial jobs in place.
Safe, rigorous assessment remains essential. Patients awaiting treatment are not a joke. The target is the old habit of making one process finish its tea before another process could enter the building.
The clipboard accepts that time moves forwards
“We have placed Licensing and Value on adjacent escalators,” said Dr Peregrine Double Queue, Consultant in Regulatory Choreography. “They may wave, but exchanging sandwiches still requires Form MED TOAST 7.”
The earlier alignment should help some medicines reach patients faster when they meet the relevant tests. That is the important result. It is more useful than a flowchart where Wednesday must provide evidence that Thursday exists.
Companies can register earlier with both organisations. One dossier arrived on a trolley large enough to need indicators, a reversing alarm and a separate evidence base for turning corners.
The first parallel application reached both desks together. Staff checked the calendar, the regulations and perhaps the ceiling. No rule required one regulator to hide until the other shouted done.
The process gets two working legs
Faster access does not mean reduced standards. It means the appropriate assessments can be better coordinated. This is a rare public sector sentence that deserves to be printed on a mug, though only after both mug regulators finish their separate reviews.
The escalators reached the top together. A third committee asked everyone to take the stairs back down for stakeholder alignment. It has since been advised that this was not the spirit of the plan.
Read the real story: The regulators’ plan for faster medicine access.
